Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C

Digestion

Volumn 71, Issue 2, 2005, Pages 124-130

  Reif, Shimon ^a   Somech, Raz ^a   Brazovski, Eli ^a   Reich, Reuven ^b   Belson, Amir ^a   Konikoff, Fred M ^c   Kessler, Ada ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cirrhosis; Fibrosis; Matrix metalloproteinase 2; Matrix metalloproteinase 9

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; LIVER ENZYME;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; MEASUREMENT; PRIORITY JOURNAL; VIRUS INFECTION; ZYMOGRAPHY;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED;

EID: 18744413561     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084626     Document Type: Article

References (57)

1. Friedman SL: The cellular basis of hepatic fibrosis. N Engl J Med 1993;328:1828-1835.
2. Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-2250.
3. Eng FJ, Friedman SL. Fibrogenesis I: New insight into hepatic stellate cell activation; the simple becomes complex. Am J Physiol 2000; 279:G7-G11.
4. Li D, Friedman SL: Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects of therapy. J Gastroenterol Hepatol 1999;14:618-633.
5. Iredale JP: Tissue inhibitor of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997;29:43-54.
6. Arthur MJP: Fibrogenesis: Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol 2000;279:G245-G249.
7. Iredale JP, Renyon RC, Pickering J, McCullen M, Northrop M, Pawlcy S, Hovell C, Arthur MJP: Mechanism of spontaneous resolution of rat liver fibrosis: Hepatic stellate cells apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102:538-549.
8. Dufour JF, DeLellis R, Kaplan MM: Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998; 43:2573-2576.
9. Dufour JF, DeLellis R, Kaplan MM: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997;127:981-985.
10. Toccaceli F, Laghi V, Capurso L, Koch M, Sereno S, Scuderi M: Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepatitis 2003;10:126-133.
11. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J: Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32: 1131-1137.
12. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, Schoonhoven R, Brenner DA, Fried MW, Burkhardt E: Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001;35:749-755.
13. Hayassaka A, Saisho H: Serum markers as tools to monitor liver fibrosis. Digestion 1998; 59:381-384.
14. Schuppan D, Stolzel U, Oesterling C, Somasundaram R: Serum assay for liver fibrosis. J Hepatol 1995;22:82-88.
15. Benyon RC, Arthur MJP: Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001;21:373-382.
16. Arthur MJP: Collagenases and liver fibrosis. J Hepatol 1995;22(suppl 2):43-48.
17. Hironaka K, Sakaida I, Matsumura Y, Kaino S, Miyamoto K, Okita K: Enhanced interstitial collgenase (matrix metalloproteinase-13) production of kupffer cell by gadolinium chloride prevents pig serum-induced rat liver fibrosis. Biochem Biophys Rev Commun 2000;267: 290-295.
18. Nagase H, Woessner JF: Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
19. Arthur MJ: Matrix degradation in liver: A role in injury and repair. Hepatology 1997;26: 1069-1071.
20. Desmet VJ, Gerber M, Hoofnagle JH: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1991;19:1513-1520.
21. Ballin M, Gomez DE, Sinha CC, Thorgeirsson UP: Ras oncogene mediated activation of a 92 kDa metalloproteinase showing correlation with the malignant phenotype. Biochem Biophys Res Commun 1988;154:832-838.
22. Iredale JP: Cirrhosis: New research provides a basis for rational and targeted treatments. BMJ 2003;327:143-147.
23. Schuppan D, Ruhel M, Sumasundram R, Hahn EG: Matrix as modulator of stellate cells and hepatic fibrogenesis. Semin Liver Dis 2001;21:351-372.
24. METAVIR Cooperative Study Group: Intraobserver and interobserver variation in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15-20.
25. Wu J, Danielsson A: Detection of hepatic fibrogenesis: A review of available techniques. Scand J Gastroenterol 1995;30:817-825.
26. Rosenberg W, Burt A, Becka M, Vollker M, Arthur MJP: Automated assays of serum markers of liver fibrosis. Hepatology 2000;32: 183A.
27. Hayasaka A, Saisho H: Serum markers as tools to monitor liver fibrosis. Digestion 1998;59: 381-384.
28. Poynard T, Yuen MF, Ratziu V, Lai CL: Viral hepatitis C. Lancet 2003;362:2095-2100.
29. Lauer GM, Walker BD: Hepatitis C infection. N Engl J Med 2001;345:41-52.
30. Marcellin P, Asselah T, Boyer N: Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:s47-s56.
31. Ghany G, Kleiner DE, Alter H, Doo E, Khokar F, Promart K, Herion D, Park Y, Liang JK, Hoofnagle JH: Progression of fibrosis in hepatitis C. Gastroenterology 2002;124:97-104.
32. Fontana RJ, Lol SFK: Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002;36:s57-s64.
33. Imbert Bismut I, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-1075.
34. Flamm SL: Chronic hepatitis C infection. JAMA 2003;289;2413-2417.
35. Afdahl NH: Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood test? Hepatology 2003;37:972-974.
36. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J: Rates and risk factors of liver fibrosis profession in patients with chronic hepatitis C. J Hepatol 2001;34: 730-739.
37. Li D, Friedman SL: Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy. J Gastroenterol Hepatol 1999:14:618-633.
38. Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi SH, Seiki M, Ooshima A, Watannabe A: Increased expression of matrix metalloproteinase II in experimental liver fibrosis in rats. Hepatology 1995;21:787-795.
39. Kossakowska AE, Edwards DR, Lee SS, Urbanski LS, Stabbler AL, Zhang CL, Phillips BW, Zhang Y, Urbanski SJ: Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998;153:1895-1902.
40. Herbst H, Wege T, Milani S, Pellegrini G, Orzechowski HD, Bechstein WO, Neuhaus P, Gressner AM, Schuppan D: Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol 1997; 150:1647-1659.
41. Ebata M, Fukuda Y, Nakano I, Katano Y, Fujimoto N, Hayakawa T: Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinases-2 in patients with liver disease. Liver 1997;17:293-299.
42. Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nnambu S, Sato H, Seiki M, Watanabe A: Dual expression of matrix metalloproteinase-2 and membrane-type 1 matrix metalloproteinase in fibrotic human livers. Hepatology 1997;26: 1521-1529.
43. Murawaki Y, Yamada S, Ikuta Y, Kawasaki H: Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol. 1999;30: 1090-1098.
44. Murawaki Y, Ikuta Y, Kawasaki H: Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin Chim Acta 1999;281:109-120.
45. Preaux AM, Mallat A, Nhieu JT, D'Ortho MP, Hembry RM, Mavier P: Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 1999;30:944-1099.
46. Walsh KM, Timms P, Campbell S, Macsween RN, Morris AJ: Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: Comparison using ROC analysis. Dig Dis Sci 1999;44:624-630.
47. Lichtinghagen R, Hueel O, Seifert T, Haberkorn CI, Michels D, Flemming P, Bahr M, Boeker KH: Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 2000;46:183-192.
48. Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, Masuzawa M, Yoshihara H, Naito M, Miyamoto T, Inoue A, Asai A, Hijioka T, Fusamoto H, Kamada T: Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997;26:574-583.
49. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. the OBSVIRC, METAVIR, CLINVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
50. Goetzl EJ, Banda MJ, Lapert D: Matrix metalloproteinase in immunity. J Immunol 1996; 156:1-4.
51. Kieseier BC, Paul R, Koedel U, Seifert T, Clements JM, Gearing AJ, Pfister HW, Hartung HP: Differential expression of matrix metalloproteinases in bacterial meningitis. Brain 1999;122:1579-1587.
52. Takafuji S, Miyakuni Y, Nakagawa T: Matrix metalloproteinase-9 release from human leukocytes. J Invest Allergol Clin Immunol 2003; 13:50-55.
53. Xie B, Laouar A, Huberman E: Autocrine regulation of macrophage differentiation and 92-kDa gelatinase production by tumor necrosis factor-alpha via alpha5 beta1 integrin in HL-60 cells. J Biol Chem 1998;273:11583-11588.
54. Borden P, Heller RA: Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryotic Gene Expression 1997;7:159-178.
55. McKallip RJ, Do Y, Fisher MT, Robertson JL, Nagarkatti PS, Nagarkatti M: Role of CD44 in activation-induced cell death: CD44-deficient mice exhibit enhanced T cell response to conventional and superantigens. Int Immunol 2002;14:1015-1026.
56. Yu Q, Stamenkovic I: Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13:35-48.
57. Mohammed FF, Smoker DS, Khokha R: Metalloproteinases, inflammation and rheumatoid arthritis. Ann Rheum Dis 2003;62:43-47.